Skip to main content

Table 3 Summary of adverse events in safety population

From: Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial

Group Oxygen group (n = 54) Hydrogen/oxygen group (n = 54)
Number of patients, n (%)
 Any adverse events 42 (77.8%) 34 (63.0%)
 Main AEs
  Hypokalemia 3 (5.6%) 2 (3.7%)
  Abnormal liver function 3 (5.6%) 1 (1.9%)
  Upper respiratory infection 3 (5.6%) 3 (5.6%)
  Elevated C-reactive protein 2 (3.7%) 4 (7.4%)
  Elevated blood pressure 2 (3.7%) 2 (3.7%)
  Cough 2 (3.7%) 2 (3.7%)
  Phlegm-retention 3 (5.6%) 0 (0.0%)
  Wheezing 4 (7.4%) 0 (0.0%)
  Agrypnia 2 (3.7%) 2 (3.7%)
 Any severe adverse events 7 (13.0%) 2 (3.7%)
  Abnormal liver function 1 (1.9%) 0 (0.0%)
  Infection (lung, upper respiratory) 3 (5.6%) 0 (0.0%)
  Bacterial infection 1 (1.9%) 0 (0.0%)
  Pulmonary inflammation 0 (0.0%) 1 (1.9%)
  Wheezing 2 (3.7%) 0 (0.0%)
  Ileus 0 (0.0%) 1 (1.9%)
 Any device-related adverse events 3 (5.6%) 2 (3.7%)
 Any adverse events leading to withdrawal 2 (3.7%) 2 (3.7%)
Number of events, n
 Any adverse events 82 63
 An severe adverse event 7 2
 Any device-related adverse events 3 3
Upper respiratory tract infection 31(14.69) 26(20.31)